Latham & Watkins represented Essex Property, while Alston & Bird represented an underwriting syndicate led by Wells Fargo, JP Morgan, PNC Capital Markets LLC, US Bancorp,...
Essex Property’s $350 Million Investment-Grade Bond Offering
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Structure Therapeutics’ US$300 Million Private Placement Equity Financing
Latham & Watkins LLP represents Jefferies LLC and Leerink Partners LLC acting as placement agents in the financing. Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global...
HilleVax’s €100 Million Common Stock Public Offering
Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock. HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Janux Therapeutics’ $60 Million Offering of Common Stock and Pre-Funded Warrants
Cooley advised Janux, and Latham & Watkins advised the underwriter on the offering. Janux Therapeutics, Inc. (Nasdaq: JANX) has announced the pricing of an underwritten offering of...
Phathom Pharmaceuticals’ $130 Million Public Offering of Common Stock
Latham & Watkins advises Phathom Pharmaceuticals in pricing of US$130 million public offering of common stock. Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and...
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
Structure Therapeutics’ $185.3 Million IPO
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
Cytokinetics’ $540 Million Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its...
RIDA Chula Vista’s $1.2 Billion Development and Financing of the Gaylord Pacific Resort Hotel and Convention Center
Latham & Watkins represented RIDA Chula Vista in the transaction. The City of Chula Vista and the Port of San Diego have announced the successful completion of...
Extra Space’s $400 Million Senior Notes Offering
Latham & Watkins represented Extra Space in the offering. Extra Space Storage Inc., a leading owner and operator of self-storage facilities in the United States and a...
Travere Therapeutics’ $275 Million Convertible Senior Notes Offering
Latham & Watkins represented the underwriters in the offering. Travere Therapeutics, Inc. executed its offering of US$275 million aggregate principal amount of 2.25% convertible senior notes due...